Skip to content
Screener

NeoGenomics NEO Reportable Segment — Other General and Administrative Expense

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other General and Administrative Expense
$2.06M-8.1%
Employers Holdings logo
EIGInsurance Operations — Other General and Administrative Expense
$2.5M+8.7%
Grindr logo
GRNDReportable Segment — Other general and administrative expense
$7.62M+64.3%
Archer Aviation logo
ACHRReportable Segment — Other general and administrative expense
$48.3M+100%
Veracyte logo
VCYTReportable Segment — Other general and administrative expenses
$13.47M-38.5%
Roivant Sciences logo
ROIVReportable Segment — Other general and administrative expenses
$34.71M+5.7%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:OtherGeneralAndAdministrativeExpense.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Depreciation8,5779,14117,35718,507
Stock-based compensation8,21612,21517,85222,969
Other cost of revenue(1)101,83195,525199,715181,342
Other general and administrative(1)48,56952,83697,614103,585
Other research and development(1)9,9347,85918,39316,961
Other sales and marketing(1)26,66623,21750,14244,927
Impairment charges20,04120,041
Loss from operations(9,771)(47,628)(28,012)(75,453)

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's reportable segment — other general and administrative expense?
NeoGenomics (NEO) reported reportable segment — other general and administrative expense of $48.57M in Q2 2026.
How has NeoGenomics's reportable segment — other general and administrative expense changed year-over-year?
NeoGenomics's reportable segment — other general and administrative expense decreased by 8.1% year-over-year, from $52.84M to $48.57M.
What is the long-term trend for NeoGenomics's reportable segment — other general and administrative expense?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — other general and administrative expense has grown at a 3.4% compound annual growth rate (CAGR), from $185.91M to $205.41M.
What does reportable segment — other general and administrative expense mean?
Covers the overhead costs required to support the segment's operations, including corporate functions, legal, and administrative support. Tracking this helps assess the segment's ability to scale operations without disproportionately increasing fixed costs.

Ask your AI about NeoGenomics's reportable segment — other general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude